For the Inventor, By the Inventor

Enter assignee name

Redwood City, CA, United States of America

Relypsa, Inc.

Calculating rank

USPTO Granted Patents = 32

% Expired Patents = 31.3

CIPO Patents = 10

EPO Patents = 14

Trademarks = 1

Forward Citations = 195

Loading Chart...

Loading Chart...

38 inventors (with patents filed for the assignee):

Dominique Charmot (21 out of 113 patents)

Mingjun Liu (21 out of 33 patents)

Gerrit Klaerner (18 out of 50 patents)

4. Eric F Connor (17 out of 45 patents)

5. Han-Ting Chang (12 out of 32 patents)

6. Michael James Cope (10 out of 26 patents)

7. Futian Liu (9 out of 33 patents)

8. Jerry M Buysse (8 out of 28 patents)

9. Han Ting Chang (8 out of 30 patents)

10. Paul Mansky (7 out of 54 patents)

11. Kalpesh N Biyani (6 out of 24 patents)

12. Jun Shao (6 out of 13 patents)

13. YongQi Mu (6 out of 95 patents)

14. John Fordtran (6 out of 9 patents)

15. Faleh Salaymeh (5 out of 6 patents)

Core Competencies:

Bile Acid Sequestrants

Potassium Ion Removal

Hypertension Treatment

Hyperkalemia

Polymeric Esters

Fluorinated Acrylates

Core-Shell Composites

Ion Imbalances

Amine Polymers

Polyfluoroacrylate

Ion Binding Compositions

Polyvinylamine

32 patents: Sort by Forward Citations

1. 10272103 - Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants (2019-04-30),

2. 10058567 - Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal (2018-08-28),

3. 9925212 - Potassium-binding agents for treating hypertension and hyperkalemia (2018-03-27),

4. 9908951 - Process for converting a polymeric ester to a polymeric acid (2018-03-06),

5. 9738584 - Fluorination of acrylate esters and derivatives (2017-08-22),

6. 9655920 - Amine polymers for use as bile acid sequestrants (2017-05-23),

7. 9492476 - Potassium-binding agents for treating hypertension and hyperkalemia (2016-11-15),

8. 9464040 - Fluorination of acrylate esters and derivatives (2016-10-11),

9. 9453092 - Process for converting a polymeric ester to a polymeric acid (2016-09-27),

10. 9301974 - Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal (2016-04-05),

11. 9228028 - Continuous process for preparing polyfluoroacrylate particles (2016-01-05),

12. 9181364 - Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants (2015-11-10),

13. 9061990 - Fluorination of acrylate esters and derivatives (2015-06-23),

14. 8889115 - Ion binding polymers and uses thereof (2014-11-18),

15. 8778324 - Ion binding polymers and uses thereof (2014-07-15),

Company Overview

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, focused on developing innovative therapies for patients with serious medical conditions. The company specializes in the research and manufacture of novel treatments aimed at addressing unmet medical needs, particularly in the fields of renal and cardiovascular health. Relypsa's commitment to advancing healthcare solutions is reflected in its dedication to scientific excellence and patient-centered approaches.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

32 Patents

#64 in Redwood City, CA

#2,535 in California

#10,607 in US

#20,697 in the World

Redwood City, CA, United States of America

Relypsa, Inc.

Forward Citations = 195

38 inventors:

Dominique Charmot (21 out of 113 patents)

Mingjun Liu (21 out of 33 patents)

Gerrit Klaerner (18 out of 50 patents)

4. Eric F Connor (17 out of 45 patents)

5. Han-Ting Chang (12 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Relypsa, Inc.. Retrieved from https://idiyas.com/company/relypsa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…